|
1
|
Waldmann T, Scholten I, Kappes F, Hu HG
and Knippers R: The DEK protein-an abundant and ubiquitous
constituent of mammalian chromatin. Gene. 343:1–9. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
von Lindern M, Breems D, van Baal S,
Adriaansen H and Grosveld G: Characterization of the translocation
breakpoint sequences of two DEK-CAN fusion genes present in t(6;9)
acute myeloid leukemia and a SET-CAN fusion gene found in a case of
acute undifferentiated leukemia. Genes Chromosomes Cancer.
5:227–234. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vinnedge Privette LM, Kappes F, Nassar N
and Wells SI: Stacking the DEK: From chromatin topology to cancer
stem cells. Cell Cycle. 12:51–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grottke C, Mantwill K, Dietel M,
Schadendorf D and Lage H: Identification of differentially
expressed genes in human melanoma cells with acquired resistance to
various antineoplastic drugs. Int J Cancer. 88:535–546. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang X, Huang SH, Yu LQ, Liu J, Diao Y and
Sun CF: Relationship between DEK oncogene expression and oral
squamous cell carcinoma. Shanghai Kou Qiang Yi Xue. 23:75–79.
2014.(In Chinese). PubMed/NCBI
|
|
6
|
Piao J, Shang Y, Liu S, Piao Y, Cui X, Li
Y and Lin Z: High expression of DEK predicts poor prognosis of
gastric adenocarcinoma. Diagn Pathol. 9:672014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y,
Li J and Lin Z: DEK over expression as an independent biomarker for
poor prognosis in colorectal cancer. BMC Cancer. 13:3662013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vinnedge Privette LM, McClaine R, Wagh PK,
Wikenheiser-Brokamp KA, Waltz SE and Wells SI: The human DEK
oncogene stimulates β-catenin signaling, invasion and mammosphere
formation in breast cancer. Oncogene. 30:2741–2752. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shibata T, Kokubu A, Miyamoto M, Hosoda F,
Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, et al:
DEK oncoprotein regulates transcriptional modifiers and sustains
tumor initiation activity in high-grade neuroendocrine carcinoma of
the lung. Oncogene. 29:4671–4681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu Q, Li Z, Lin H, Han L, Liu S and Lin Z:
DEK overexpression in uterine cervical cancers. Pathol Int.
58:378–382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orlic M, Spencer CE, Wang L and Gallie BL:
Expression analysis of 6p22 genomic gain in retinoblastoma. Genes
Chromosomes Cancer. 45:72–82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carro MS, Spiga FM, Quarto M, Di Ninni V,
Volorio S, Alcalay M and Müller H: DEK Expression is controlled by
E2F and deregulated in diverse tumor types. Cell Cycle.
5:1202–1207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sanchez-Carbayo M, Socci ND, Lozano JJ, Li
W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G
and Cordon-Cardo C: Gene discovery in bladder cancer progression
using cDNA microarrays. Am J Pathol. 163:505–516. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Larramendy ML, Niini T, Elonen E, Nagy B,
Ollila J, Vihinen M and Knuutila S: Overexpression of
translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK,
but absence of the translocations in acute myeloid leukemia. A
microarray analysis. Haematologica. 87:569–577. 2002.PubMed/NCBI
|
|
15
|
Kroes RA, Jastrow A, McLone MG, Yamamoto
H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J
and Moskal JR: The identification of novel therapeutic targets for
the treatment of malignant brain tumors. Cancer Lett. 156:191–198.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kondoh N, Wakatsuki T, Ryo A, Hada A,
Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita
M, et al: Identification and characterization of genes associated
with human hepatocellular carcinogenesis. Cancer Res. 59:4990–4996.
1999.PubMed/NCBI
|
|
17
|
Wise-Draper TM, Mintz-Cole RA, Morris TA,
Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld
GC and Wells SI: Overexpression of the cellular DEK protein
promotes epithelial transformation in vitro and in vivo. Cancer
Res. 69:1792–1799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wise-Draper TM, Allen HV, Thobe MN, Jones
EE, Habash KB, Münger K and Wells SI: The human DEK proto-oncogene
is a senescence inhibitor and an upregulated target of high-risk
human papillomavirus E7. J Virol. 79:14309–14317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wise-Draper TM, Allen HV, Jones EE, Habash
KB, Matsuo H and Wells SI: Apoptosis inhibition by the human DEK
oncoprotein involves interference with p53 functions. Mol Cell
Biol. 26:7506–7519. 2016. View Article : Google Scholar
|
|
20
|
Liu K, Feng T, Liu J, Zhong M and Zhang S:
Silencing of the DEK gene induces apoptosis and senescence in CaSki
cervical carcinoma cells via the up-regulation of NF-κB p65. Biosci
Rep. 32:323–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim DW, Chae JI, Kim JY, Pak JH, Koo DB,
Bahk YY and Seo SB: Proteomic analysis of apoptosis related
proteins regulated by proto-oncogene protein DEK. J Cell Biochem.
106:1048–1059. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waldmann T, Eckerich C, Baack M and Gruss
C: The ubiquitous chromatin protein DEK alters the structure of DNA
by introducing positive supercoils. J Biol Chem. 277:24988–24994.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kavanaugh GM, Wise-Draper TM, Morreale RJ,
Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF,
Wells JM, et al: The human DEK oncogene regulates DNA damage
response signaling and repair. Nucleic Acids Res. 39:7465–7476.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kappes F, Fahrer J, Khodadoust MS, Tabbert
A, Strasser C, Mor-Vaknin N, Moreno-Villanueva M, Bürkle A,
Markovitz DM and Ferrando-May E: DEK is a poly(ADP-ribose) acceptor
in apoptosis and mediates resistance to genotoxic stress. Mol Cell
Biol. 28:3245–3257. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khodadoust MS, Verhaegen M, Kappes F,
Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz
DM and Soengas MS: Melanoma proliferation and chemoresistance
controlled by the DEK oncogene. Cancer Res. 69:6405–6413. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martinez-Useros J, Rodriguez-Remirez M,
Borrero-Palacios A, Moreno I, Cebrian A, del Pulgar Gomez T, del
Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, et al: DEK is
a potential marker for aggressive phenotype and irinotecan-based
therapy response in metastatic colorectal cancer. BMC Cancer.
14:9652014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin D, Dong X, Wang K, Wyatt AW, Crea F,
Xue H, Wang Y, Wu R, Bell RH, Haegert A, et al: Identification of
DEK as a potential therapeutic target for neuroendocrine prostate
cancer. Oncotarget. 6:1806–1820. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Qi D, Qi J, Mao Z, Li X, Zhang J,
Li J and Gao W: Significance of DEK overexpression for the
prognostic evaluation of non-small cell lung carcinoma. Oncol Rep.
35:155–162. 2016. View Article : Google Scholar : PubMed/NCBI
|
